Ad
related to: astrazeneca stock
Search results
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 22 hours agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 5 hours agoThe institutional investor owned 1,390,959 shares of the company’s stock after buying an additional 95,652 shares during the period. First Trust Advisors LP’s holdings in ...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 1 day agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 3 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 1 day agoOn Monday, Deutsche Bank reiterated a Hold rating and a price target of GBP110.00 on stock of ...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 4 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
InvestorPlace· 2 hours agoThis however holds true for high-quality blue-chip and growth stocks. On the other hand, in an...
Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September -...
Benzinga· 36 minutes agoNovavax Inc. NVAX shares surged after the company announced its plans to deliver a...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 14 hours agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...